Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples.
The SARS-CoV-2 pandemic, which started in December 2019, has been posing significant challenges to the health care system worldwide. As the pandemic spreads with rapidly increasing number of positive cases, early diagnosis of infected patients is crucial to successfully limit the spread of the virus...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0262399 |
| _version_ | 1818331154341691392 |
|---|---|
| author | Magyar Nóra Dániel Déri Dániel Sándor Veres Zoltán Kis Erzsébet Barcsay Bernadett Pályi |
| author_facet | Magyar Nóra Dániel Déri Dániel Sándor Veres Zoltán Kis Erzsébet Barcsay Bernadett Pályi |
| author_sort | Magyar Nóra |
| collection | DOAJ |
| description | The SARS-CoV-2 pandemic, which started in December 2019, has been posing significant challenges to the health care system worldwide. As the pandemic spreads with rapidly increasing number of positive cases, early diagnosis of infected patients is crucial to successfully limit the spread of the virus. Although the real-time reverse-transcription polymerase chain reaction (RT-qPCR) is the recommended laboratory method to diagnose COVID-19 infection, many factors such as availability of laboratory equipment, reagents and trained personnel affect the use of time-consuming molecular techniques. To facilitate on-the-spot diagnosis of COVID-19, SARS-CoV-2 rapid antigen tests were developed by several different manufacturers. The evaluation of such rapid tests is particularly important due to the recent unanimous agreement by the European Commission Member States on a recommendation setting out a framework for the use of antigen rapid tests that contains a list of the mutually recognized assays and the basis of independent validation protocols. To evaluate the on-field performance of ten commercially available SARS-CoV-2 antigen rapid tests (CLINITEST Rapid COVID-19 Antigen Test, GenBody COVID-19 Antigen Test, GENEDIA W COVID-19 Ag Test, Healgen Coronavirus Antigen Rapid Test, Humasis COVID-19 Ag Test, VivaDiag SARS-CoV-2 Ag Rapid Test, Helix i-SARS-CoV-2 Ag Rapid Test, Roche SARS-CoV-2 Rapid Antigen Test, Abbot COVID-19 Ag Rapid Test and Vazyme SARS-CoV-2 Antigen Detection Kit) and compare with RT-qPCR as a reference method, the Hungarian National Public Health Center provided 1,597 antigen rapid tests to the National Ambulance Service, COVID-testing trucks and two hospitals treating COVID-19 patients. Sensitivity, specificity and accuracy were determined by performing the rapid test directly from nasopharyngeal swab samples of symptomatic individuals. For strongly positive samples (Ct < 25) sensitivities ranged between 66.7% and 100%, while for positive samples (Ct < 30) they gave a maximum sensitivity of 87.5%. The specificity of the tests was ranging between 79% to 100%. The results presented here are of high importance to the European Commission and also help governmental decision-making regarding the application of the proper rapid tests for screening different at-risk populations. Nonetheless, SARS-Cov-2 rapid tests play an important role in early and on-the-spot diagnosis of potentially infected individuals. |
| first_indexed | 2024-12-13T13:15:20Z |
| format | Article |
| id | doaj.art-90f5892a46da41fe94b4bff1cfa4115a |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T13:15:20Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-90f5892a46da41fe94b4bff1cfa4115a2022-12-21T23:44:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01172e026239910.1371/journal.pone.0262399Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples.Magyar NóraDániel DériDániel Sándor VeresZoltán KisErzsébet BarcsayBernadett PályiThe SARS-CoV-2 pandemic, which started in December 2019, has been posing significant challenges to the health care system worldwide. As the pandemic spreads with rapidly increasing number of positive cases, early diagnosis of infected patients is crucial to successfully limit the spread of the virus. Although the real-time reverse-transcription polymerase chain reaction (RT-qPCR) is the recommended laboratory method to diagnose COVID-19 infection, many factors such as availability of laboratory equipment, reagents and trained personnel affect the use of time-consuming molecular techniques. To facilitate on-the-spot diagnosis of COVID-19, SARS-CoV-2 rapid antigen tests were developed by several different manufacturers. The evaluation of such rapid tests is particularly important due to the recent unanimous agreement by the European Commission Member States on a recommendation setting out a framework for the use of antigen rapid tests that contains a list of the mutually recognized assays and the basis of independent validation protocols. To evaluate the on-field performance of ten commercially available SARS-CoV-2 antigen rapid tests (CLINITEST Rapid COVID-19 Antigen Test, GenBody COVID-19 Antigen Test, GENEDIA W COVID-19 Ag Test, Healgen Coronavirus Antigen Rapid Test, Humasis COVID-19 Ag Test, VivaDiag SARS-CoV-2 Ag Rapid Test, Helix i-SARS-CoV-2 Ag Rapid Test, Roche SARS-CoV-2 Rapid Antigen Test, Abbot COVID-19 Ag Rapid Test and Vazyme SARS-CoV-2 Antigen Detection Kit) and compare with RT-qPCR as a reference method, the Hungarian National Public Health Center provided 1,597 antigen rapid tests to the National Ambulance Service, COVID-testing trucks and two hospitals treating COVID-19 patients. Sensitivity, specificity and accuracy were determined by performing the rapid test directly from nasopharyngeal swab samples of symptomatic individuals. For strongly positive samples (Ct < 25) sensitivities ranged between 66.7% and 100%, while for positive samples (Ct < 30) they gave a maximum sensitivity of 87.5%. The specificity of the tests was ranging between 79% to 100%. The results presented here are of high importance to the European Commission and also help governmental decision-making regarding the application of the proper rapid tests for screening different at-risk populations. Nonetheless, SARS-Cov-2 rapid tests play an important role in early and on-the-spot diagnosis of potentially infected individuals.https://doi.org/10.1371/journal.pone.0262399 |
| spellingShingle | Magyar Nóra Dániel Déri Dániel Sándor Veres Zoltán Kis Erzsébet Barcsay Bernadett Pályi Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples. PLoS ONE |
| title | Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples. |
| title_full | Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples. |
| title_fullStr | Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples. |
| title_full_unstemmed | Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples. |
| title_short | Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples. |
| title_sort | evaluating the field performance of multiple sars cov 2 antigen rapid tests using nasopharyngeal swab samples |
| url | https://doi.org/10.1371/journal.pone.0262399 |
| work_keys_str_mv | AT magyarnora evaluatingthefieldperformanceofmultiplesarscov2antigenrapidtestsusingnasopharyngealswabsamples AT danielderi evaluatingthefieldperformanceofmultiplesarscov2antigenrapidtestsusingnasopharyngealswabsamples AT danielsandorveres evaluatingthefieldperformanceofmultiplesarscov2antigenrapidtestsusingnasopharyngealswabsamples AT zoltankis evaluatingthefieldperformanceofmultiplesarscov2antigenrapidtestsusingnasopharyngealswabsamples AT erzsebetbarcsay evaluatingthefieldperformanceofmultiplesarscov2antigenrapidtestsusingnasopharyngealswabsamples AT bernadettpalyi evaluatingthefieldperformanceofmultiplesarscov2antigenrapidtestsusingnasopharyngealswabsamples |